secwatch.observer — SEC 8-K summary
======================================

Issuer:     INCYTE CORP (INCY)
CIK:        0000879169
Form:       8-K
Filed at:   2023-10-31T23:59:59+00:00
Accession:  0000879169-23-000038
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Incyte Q3 2023 revenues up 12% to $919M; Jakafi guidance tightened to $2.59-2.62B
--------------------------------------------------------------------------------

- Total GAAP revenues of $919M (+12% YoY); GAAP net income $171M ($0.76 diluted EPS).
- Jakafi net product revs $636M (+3% YoY); Opzelura $92M (+141% YoY) on AD/vitiligo demand.
- Non-GAAP diluted EPS $1.10 vs $0.60 in Q3 2022; operating income up 63% to $273M.
- FY 2023 Jakafi guidance tightened to $2.59-2.62B from $2.58-2.63B; other guidance unchanged.
- Phase 2 povorcitinib in prurigo nodularis met primary endpoint; Phase 3 planned for 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/879169/000087916923000038/0000879169-23-000038-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/879169/000087916923000038/incy-20231031.htm
  HTML page:      https://secwatch.observer/filing/0000879169-23-000038

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer